Posts tagged BenevolentAI
Our team behind the scenes at SXSW | Target Identification, Literature Knowledge Inference

Watch our team investigate the target identification process for GBM using machine learning methods. Their aim was to identify genes or proteins involved in the development of glioblastoma stem cells - a type of cell at the origin of GBM that are resistant to the current treatments.

Read More
Our team behind the scenes at SXSW | Patient Stratification in Target ID, OMICS data

BenevolentAI develops AI models to help scientists better define underlying mechanisms of disease in very specific patients groups. Looking at patient clinical and biomedical data we try to dig into the molecular level detail to redefine the disease and better endotyping for two main purposes

Read More
How AI is revolutionising drug discovery

"If you come into my world, in biomedicine, everyday thousands of papers are uploaded in portal like PubMed, new genome sequences, new biomarkers, new clinical trial data, we are drowning in data [...] Artificial intelligence could be the solution for a broken drug discovery model."

Read More
NVIDIA DGX-1 - Unboxing at BenevolentAI

Watch this clip of the very first ‘supercomputer in a box’ – the NVIDIA DGX-1 – being delivered and unboxed by our resident experts Derek Wise and Dean Plumbley at BenevolentAI HQ. Being the first delivery of its kind in Europe, Derek and Dean explain how the processing power of the DGX-1 will hugely accelerate the work they and their colleagues are doing at the company.

Read More